Vraylar sales skyrockets, revenue rises
Foreign Minister sees "extraordinary economic opportunities" in Uzbekistan
Vraylar sequential growth to continue after lockdown
Wood remains on throne in June
Rating is overweight
Turnover drops in May after rally in March and April
HUF 63.06 per share
Target price, rating remain unchanged
Recommendation raised to overweight
It revises EBIT forecast upwardly, though
Exceeds profit expectations
First quarter turned out well, according to analysts
Richter-Helm joint venture to produce Inovio's DNA vaccine
In USD 16.5 mn deal
Measures introduced to protect employees and to reduce risk of any potential contagion
According to draft resolutions for general meeting
Endorses spending of Vraylar cash
For treatment of uterine fibroids and endometriosis
Including Richter, OTP, Mol